Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Glofitamab-gxbm |
| Synonyms | |
| Therapy Description |
Columvi (glofitamab-gxbm) is a bispecific antibody that binds the tumor-associated antigen, MS4A1 (CD20), and CD3 on T-cells to stimulate T-cell killing of CD20-expressing tumor cells (PMID: 36507690). Columvi (glofitamab-gxbm) is FDA-approved for use in patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Glofitamab-gxbm | Columvi | RO 7082859|RO-7082859|RO7082859 | CD20 Antibody 25 CD3 Antibody 107 | Columvi (glofitamab-gxbm) is a bispecific antibody that binds the tumor-associated antigen, MS4A1 (CD20), and CD3 on T-cells to stimulate T-cell killing of CD20-expressing tumor cells (PMID: 36507690). Columvi (glofitamab-gxbm) is FDA-approved for use in patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03467373 | Phase I | Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas | Completed | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 0 |
| NCT06624085 | Phase I | Obinutuzumab Gemcitabine + Glofitamab-gxbm + Oxaliplatin Glofitamab-gxbm | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT06670105 | Phase II | Glofitamab-gxbm | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients with Large B-cell Lymphoma | Not yet recruiting | USA | 0 |
| NCT06084936 | Phase III | Obinutuzumab Glofitamab-gxbm Lenalidomide + Rituximab Bendamustine + Rituximab | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 4 |
| NCT05833763 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + Pirtobrutinib Obinutuzumab | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX) | Recruiting | AUS | 0 |
| NCT05533775 | Phase Ib/II | Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | BRA | AUS | 1 |
| NCT06534437 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + SEL24-B489 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01) | Recruiting | POL | FRA | ESP | 0 |
CKB BOOST